Abstract
Low-density lipoprotein receptor-related protein 6 (LRP6) plays a critical role in cardiovascular homeostasis. The deficiency of LRP6 is associated with a high risk of arrhythmias. However, the association between genetic variations of LRP6 and sudden cardiac death (SCD) remains unknown. This study aims to explore the association between common variants of LRP6 and the prognosis of chronic heart failure (CHF) patients. From July 2005 to December 2009, patients with CHF were enrolled from 10 hospitals in China. The single-nucleotide polymorphism (SNP) rs2302684 was selected for the evaluation of the effect of LRP6 polymorphisms on the survival in patients with CHF. A total of 1,437 patients with CHF were finally included for the analysis. During a median follow-up of 61 months (range 0.4–129 months), a total of 546 (38.0%) patients died, including 201 (36.8%) cases with SCD and 345 (63.2%) cases with non-SCD. Patients carrying A allele of rs2302684 had an increased risk of all-cause death (adjusted HR 1.452, 95% CI 1.189–1.706; P < 0.001) and SCD (adjusted HR 1.783, 95% CI 1.337–2.378; P < 0.001). Therefore, the SNP rs2302684 T>A in LRP6 indicated higher risks of all-cause death and SCD in patients with CHF. LRP6 could be added as a novel predictor of SCD and might be a potential therapeutic target in the prevention of SCD in the CHF population.
Highlights
Chronic heart failure (CHF), which may be caused by ischemic cardiomyopathy (ICM) or nonischemic cardiomyopathy (NICM), is one of the chief causes of morbidity and mortality worldwide [1, 2]
We examined the association between common variants of lipoprotein receptor-related protein 6 (LRP6) and the prognosis in patients with chronic heart failure (CHF)
No significant differences were demonstrated in age, sex distribution, BMI, LVDD, left ventricular ejection fraction (LVEF), complications, the prevalence of arrhythmias, and medication between the patients with rs2302684 wild type of TT and those with A allele (Table 1)
Summary
Chronic heart failure (CHF), which may be caused by ischemic cardiomyopathy (ICM) or nonischemic cardiomyopathy (NICM), is one of the chief causes of morbidity and mortality worldwide [1, 2]. It currently affects more than five million Americans and the prevalence is expected to increase by 25% within the 15 years [3]. This heart failure pandemic is evident in Asia and China [4]. The prediction and prevention of SCD play critical roles in the management of the LRP6 and Sudden Cardiac Death
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
